Beovu ® (brolucizumab): Updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Beovu
|
| Active substance |
Brolucizumab
|
| Therapeutic area (MeSH) |
Wet Macular Degeneration
|
| Procedure number |
EMEA/H/C/004913
|
| Regulatory outcome |
Variation
|
| DHPC type |
Type II variation
|
| Human ATC code |
S01
|
| Dissemination date |
05/11/2021
|